The total retail sales volume of antithrombotic agents (EphMRA group B01) reached 49.3 billion rubles in January–October 2025 (at retail prices, including VAT), with more than 58.3 million packs sold during the period. According to the “Retail Sales Audit of Medicinal Products in Russia (total sell-out)” database by analytics company RNC Pharma, year-on-year growth reached 6.3% in value terms and 1.7% in physical volume. By comparison, the segment grew by 21% in value and only 0.4% in packs in 2024, driven primarily by higher sales of several premium-priced products — notably Brilinta (+47% in rubles) and Eliquis (+32%).

More than 57% of the segment’s value is attributable to direct factor Xa inhibitors (subgroup B01F), which includes only three INNs. This subgroup also demonstrated the strongest volume growth (+16% in packs), largely determining the overall performance of the entire category. The key driver was rivaroxaban-based products, as consumers continued switching from Xarelto (Bayer HealthCare) to direct generic equivalents. Notably, by August 2025 the combined monthly sales volume of generics had already surpassed that of the originator product. Against this backdrop, sales of Eliquis (Pfizer) also increased, likely supported by intensive marketing efforts. By contrast, the Russian originator Xa inhibitor Dimolegin (Avexima) is still in its market entry stage; although the company is working to expand its approved indications, achieving meaningful competitive weight will require substantial promotional investment.

Significant growth was also recorded in the heparins category (+9%), though their total physical volume remains nearly twelve times lower than that of apixaban and rivaroxaban products. Within this subgroup, sodium enoxaparin products stand out — particularly Clexane (Sanofi), whose sales increased by 25% in value and 19% in packs year-on-year, despite a large number of analogues, including the Russian generic Enixum (Sotex), which posted a 50% increase in demand.

In 2025, the platelet aggregation inhibitor subgroup demonstrated a decline of 2%. This category, however, remains the absolute leader in terms of volume consumption, accounting for more than 70% of the market. The situation is highly heterogeneous: Brilinta (AstraZeneca) recorded a 25% increase in value sales versus January–October 2024, despite the launch of several direct generic competitors at the end of 2024. The overall decline in the subgroup is primarily attributable to falling sales of acetylsalicylic acid products. Among brands ranked in the top ten by value, it is also worth highlighting Vessel Due F (Alfasigma), whose retail sales increased by 19%, largely driven by a rise in physical demand.

Table. TOP-10 Antithrombotic Brands (EphMRA group B01) by Value Sales in the Russian Retail Market, January–October 2025